Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2003
Business Overview: Cardinal Health is a leading provider of products and services supporting the health care industry. Operations are organized into four segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The company distributes pharmaceuticals, medical products, and provides pharmacy management, drug delivery technologies, and automation systems.
Key Financial Metrics
| Metric (in millions) | Fiscal 2003 | Fiscal 2002 |
|---|---|---|
| Operating Revenue | $50,466.6 | $44,394.3 |
| Total Revenue (incl. bulk deliveries) | $56,737.0 | $51,135.7 |
| Net Earnings | $1,405.8 | $1,056.2 |
| Diluted EPS | $3.10 | $2.30 |
| Operating Gross Margin % | 8.9% | 9.1% |
| Net Cash from Operating Activities | $1,398.0 | $983.9 |
| Total Assets | $18,521.4 | $16,438.0 |
| Long-term Obligations | $2,471.9 | $2,207.0 |
| Shareholders' Equity | $7,758.1 | $6,393.0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11% to $56.7 billion, driven by a 14% increase in operating revenue. Growth was fueled by higher sales volume, pharmaceutical price increases (~5%), and the acquisition of Syncor International Corporation (effective Jan 1, 2003).
- Profitability: Net earnings rose 33% to $1.4 billion. Diluted earnings per share increased from $2.30 to $3.10.
- Margin Compression: Overall gross margin decreased from 9.1% to 8.9%. The Pharmaceutical Distribution segment margin declined to 4.6% (from 5.0%) due to competitive pricing, a shift to lower-margin customers, and vendor supply chain changes reducing inventory investment opportunities.
- Special Items: The company recorded a net benefit of $34.5 million from special items in 2003, primarily due to $101.5 million in litigation settlement income (vitamin antitrust claims), partially offset by $74.4 million in merger-related costs and $40.2 million in restructuring charges.
- Acquisitions: The Syncor acquisition added approximately $687.5 million in goodwill and $38.7 million in intangible assets. Certain Syncor operations were classified as discontinued operations.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management anticipates continued growth through acquisitions and internal expansion. The company expects to incur approximately $90 million in additional merger and restructuring costs in future periods.
- Share Repurchases: The Board authorized a $1.0 billion share repurchase program in August 2003. Approximately 17.0 million shares were repurchased for $1.0 billion in the first quarter of fiscal 2004.
- Key Risks:
- Regulatory: Significant exposure to changes in U.S. health care reimbursement, managed care trends, and compliance with FDA, DEA, and HIPAA regulations.
- Customer Concentration: CVS accounted for 13% of operating revenue; CVS and Walgreens accounted for 84% of bulk deliveries.
- Supplier Concentration: Pfizer accounted for 11% of total revenue; the top five suppliers accounted for 37%.
- Vendor Policies: Changes in vendor inventory management agreements may limit the company's ability to invest in inventory for price increases, negatively impacting margins.
- Legal Proceedings:
- Syncor Litigation: Multiple class actions and derivative suits allege improper payments to foreign customers and breach of fiduciary duties. The company believes these are without merit and expects insurance coverage for a portion of any liability.
- Latex Litigation: Allegiance (acquired 1999) faces 233 pending lawsuits regarding latex sensitization. Estimated liability is $0 to $20 million net of insurance.
- DuPont Litigation: Filed September 2003 alleging patent infringement and false advertising regarding surgical drapes.
Investor Verification Checklist
- Syncor Integration: Verify the progress of integrating Syncor's nuclear pharmacy services and the resolution of pending litigation regarding alleged improper payments.
- Margin Trends: Monitor the impact of vendor supply chain management policies and inventory agreements on the Pharmaceutical Distribution segment's gross margins.
- Customer Concentration: Assess the risk associated with CVS (13% of revenue) and the potential impact of any changes in their business or relationship with Cardinal.
- Restructuring Costs: Track the realization of the estimated $90 million in future merger and restructuring costs.
- Discontinued Operations: Confirm the timeline and financial outcome of the planned sale of Syncor's discontinued operations (medical imaging and overseas businesses) expected by Jan 1, 2004.